Synchron Acquires Equity Stake in ACQUANDAS

Synchron uses a minimally-invasive endovascular procedure that avoids open brain surgery

Synchron, the brain-computer interface (BCI) company developing endovascular technology to restore functionality in patients with motor impairment, today announced the acquisition of an equity stake in ACQUANDAS, a leading technology provider specializing in state-of-the-art high-precision components for the healthcare industry and other industries.

The Stentrode™ Endovascular Electrode Array (Photo: Synchron)
The Stentrode™ Endovascular Electrode Array (Photo: Synchron)

As part of the transaction, Tom Oxley, Synchron’s CEO & Founder, will join the ACQUANDAS Governance Council and Riki Banerjee, Synchron’s CTO, will join as Observer.

“As we pioneer functional endovascular neurotechnology, this investment strengthens our technology innovation and supply chain for our unique product offerings, beginning with brain-computer interfaces,” said Oxley.

“After many years of development in fabrication technology, I am thrilled to welcome Synchron on board as an investor. This major investment will not only strengthen our existing partnership but will also play a pivotal role in expanding our facilities and capabilities. It serves as a testament to the readiness of our fabrication technology and our company for the market,” said CEO & Founder Dr. Rodrigo Lima de Miranda, ACQUANDAS.

ACQUANDAS has established an entirely new generation of shape-memory, flexible metallic components suitable for use as medical devices. Their capability to manufacture miniaturized structures, such as micro-patterned Nitinol thin films, combined with high structure resolution and geometrical complexity, excellent biocompatibility and improved mechanical properties, provides Synchron with a unique product offering in the implantable medical device industry.

More News

To illustrate the type of environments in which gold nanoparticles can be used, the nanoparticles approach densely packed regions of proteins. (Image: Ferdinand Otto, UHH)
To illustrate the type of environments in which gold nanoparticles can be used, the nanoparticles approach densely packed regions of proteins. (Image: Ferdinand Otto, UHH)

"Stealth Effect"

An experiment led by a team of DESY and Universität Hamburg scientists has discovered that gold nanoparticles can move through liquid ...

Read more …
Evotec has started the search for a permanent solution for the position of CEO.

Evotec announces CEO transition

Evotec SE announced that after close to 15 years of successful service, CEO Dr Werner Lanthaler has informed the company, that he will not continue ...

Read more …
Johanna Hakanpää, scientist in charge of beamline P11, in conversation with Serghei Glinca, founder and CEO of CrystalsFirst. ( Photo: DESY)
Johanna Hakanpää, scientist in charge of beamline P11, in conversation with Serghei Glinca, founder and CEO of CrystalsFirst. ( Photo: DESY)

Cooperation for faster drug discovery

The mutual project “LigandML” receives funding by the IFB Hamburg aiming to leverage experimental capabilities for better data quality paired ...

Read more …